Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-735M | $-739M | $-610M | -1418.8% | - | -12.7% |
| 2024 | $0M | $-877M | $-846M | $-587M | -199.9% | - | 107.4% |
| 2023 | $0M | $-429M | $-408M | $-335M | -95.4% | - | -28.4% |
| 2022 | $0M | $-567M | $-570M | $-339M | -105.8% | - | - |
| 2021 | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 567.93 | 436.05 | 885.11 | 745.38 |
| Research And Development | - | 437.07 | 373.28 | 795.87 | 635.07 |
| Selling General And Administration | - | 130.86 | 62.77 | 89.24 | 110.31 |
| Total Expenses | - | 567.93 | 436.05 | 885.11 | 745.38 |
| Operating Income | - | -567.93 | -436.05 | -885.11 | -745.38 |
| Total Operating Income As Reported | - | -567.93 | -436.05 | -885.11 | -745.38 |
| EBITDA | - | -566.55 | -429.14 | -877.26 | -735.46 |
| Normalized EBITDA | - | -566.55 | -429.14 | -877.26 | -735.46 |
| EBIT | - | -567.93 | -436.05 | -885.11 | -745.38 |
| Other Non Operating Income Expenses | - | -1.91 | 26.50 | 39.42 | 8 |
| Other Income Expense | - | -1.91 | 26.50 | 39.42 | 8 |
| Pretax Income | - | -569.84 | -409.55 | -845.69 | -737.38 |
| Tax Provision | - | 0.44 | -1.38 | 0.74 | 1.44 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Net Income From Continuing And Discontinued Operation | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Net Income From Continuing Operation Net Minority Interest | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Net Income | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Net Income Common Stockholders | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Net Income Including Noncontrolling Interests | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Normalized Income | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Diluted NI Availto Com Stockholders | - | -570.28 | -408.17 | -846.42 | -738.82 |
| Basic Average Shares | 35.82 | 44.74 | 71.20 | 91.23 | - |
| Diluted Average Shares | 35.82 | 44.74 | 71.20 | 91.23 | - |
| Reconciled Depreciation | - | 1.39 | 6.91 | 7.86 | 9.92 |
| General And Administrative Expense | - | 130.86 | 62.77 | 89.24 | 110.31 |
| Other Gand A | - | 130.86 | 62.77 | 89.24 | 110.31 |
| Earnings From Equity Interest | 5.26 | 0 | 0 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Biohaven Ltd.this co. | BHVN | $1.7B | -2.32 | 32.96 | -1418.8% | -2.41 |
| SELLAS Life Sciences Group, Inc. | SLS | $1.8B | -66.17 | 25.08 | -37.9% | -60.37 |
| UFP Technologies, Inc. | UFPT | $1.7B | 25.43 | 4.10 | 16.1% | 16.79 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | -4.15 | 1.44 | -34.6% | -3.56 |
| Sionna Therapeutics, Inc. | SION | $1.7B |
| - |
| - |
| - |
| -22.66 |
| 5.56 |
| -24.5% |
| -18.75 |
| Taysha Gene Therapies, Inc. | TSHA | $1.7B | -15.53 | 6.85 | -44.1% | -13.39 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| Addus HomeCare Corporation | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Peer Median | - | -9.84 | 4.76 | -29.6% | -0.07 | |
Historically, Oct has averaged the highest return (+46.3%); Mar the lowest (-14.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.8%Positive MonthJan 2026: +4.78% | -2.6%Negative MonthFeb 2026: -2.62% | -26.6%Negative MonthMar 2026: -26.56% | +13.4%Positive MonthApr 2026: +13.36% | +14.8%Positive MonthMay 2026: +14.81% | +35.1%Positive MonthJun 2026: +35.15% | -9.3%Negative MonthJul 2026: -9.27% | +4.7%*Positive MonthAug 2026: +4.74% | — | — | — | — |
| 2025 | +2.4%Positive MonthJan 2025: +2.41% | -2.8%Negative MonthFeb 2025: -2.80% | -35.3%Negative MonthMar 2025: -35.34% | -8.0%Negative MonthApr 2025: -7.99% | -33.0%Negative MonthMay 2025: -33.05% | -4.7%Negative MonthJun 2025: -4.73% | +7.0%Positive MonthJul 2025: +7.02% | +1.9%Neutral MonthAug 2025: +1.92% | -2.5%Negative MonthSep 2025: -2.47% | +14.6%Positive MonthOct 2025: +14.59% | -41.7%Negative MonthNov 2025: -41.69% | +12.6%Positive MonthDec 2025: +12.56% |
| 2024 | +3.9%Positive MonthJan 2024: +3.93% | +8.2%Positive MonthFeb 2024: +8.23% | +13.6%Positive MonthMar 2024: +13.61% | -29.1%Negative MonthApr 2024: -29.05% | -9.5%Negative MonthMay 2024: -9.54% | -1.1%Neutral MonthJun 2024: -1.11% | +13.3%Positive MonthJul 2024: +13.31% | +0.2%Neutral MonthAug 2024: +0.18% | +26.8%Positive MonthSep 2024: +26.83% | -0.4%Neutral MonthOct 2024: -0.42% | -7.5%Negative MonthNov 2024: -7.54% | -18.8%Negative MonthDec 2024: -18.82% |
| 2023 | +37.5%Positive MonthJan 2023: +37.54% | -20.0%Negative MonthFeb 2023: -19.96% | -10.6%Negative MonthMar 2023: -10.60% | -4.2%Negative MonthApr 2023: -4.25% | +33.9%Positive MonthMay 2023: +33.87% | +36.6%Positive MonthJun 2023: +36.61% | -16.9%Negative MonthJul 2023: -16.89% | -8.0%Negative MonthAug 2023: -8.00% | +42.2%Positive MonthSep 2023: +42.21% | +1.9%Neutral MonthOct 2023: +1.92% | +25.7%Positive MonthNov 2023: +25.69% | +28.5%Positive MonthDec 2023: +28.45% |
| 2022 | — | — | — | — | — | — | — | — | — | +169.1%Positive MonthOct 2022: +169.07% | -4.5%Negative MonthNov 2022: -4.53% | -12.3%Negative MonthDec 2022: -12.26% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 5 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
